# Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery

> **NCT01387464** · PHASE2 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 60 (actual)

## Conditions studied

- Cataract

## Interventions

- **DRUG:** ISV-303
- **DRUG:** Bromday™

## Key facts

- **NCT ID:** NCT01387464
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01387464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01387464, "Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01387464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*